Conference
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
Abstract
OBJECTIVE: To evaluate changes in bone turnover and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months.
METHODS: We conducted a randomized, double-blind, placebo-controlled, phase II study of RA patients. Patients received placebo, denosumab 60 mg, or denosumab 180 mg every 6 months for 12 months and were followed up for an additional 12 months after …
Authors
Saag KG; McDermott MT; Adachi J; Lems W; Lane NE; Geusens P; Stad RK; Chen L; Huang S; Dore R
Volume
74
Pagination
pp. 604-611
Publisher
Wiley
Publication Date
April 2022
DOI
10.1002/art.41981
Conference proceedings
Arthritis & Rheumatology
Issue
4
ISSN
2326-5191